E. coli 83972
PreclinicalBiologic
E. coli 83972 is one of 18 biologic programs targeting Recurrent urinary tract infections. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Recurrent Urinary Tract Infections
#DrugCompanyPhaseTrials
1Monurol
MMeitheal
Approved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Merrem
BB. Braun Medical Inc.
Approved
Intrarosa
Alnylam PharmaceuticalsPhase 3
Estrace
Novo NordiskPhase 3
Vagifem
Novo NordiskApproved
Trimethoprim/sulfamethoxazole
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
ESTRING
UUniversity of California, San Francisco
Approved
Mannose
UUniversity of Colorado, Denver
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for E. coli 83972. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- RRegion Skane